NASDAQ:CSTL - Nasdaq - US14843C1053 - Common Stock - Currency: USD
NASDAQ:CSTL (5/29/2025, 9:58:36 AM)
16.2
-0.03 (-0.18%)
The current stock price of CSTL is 16.2 USD. In the past month the price decreased by -18.24%. In the past year, price decreased by -30.22%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
CI | THE CIGNA GROUP | 11.29 | 83.25B | ||
CVS | CVS HEALTH CORP | 9.87 | 79.43B | ||
LH | LABCORP HOLDINGS INC | 16.77 | 20.68B | ||
DGX | QUEST DIAGNOSTICS INC | 18.73 | 19.22B | ||
FMS | FRESENIUS MEDICAL CARE-ADR | 15.53 | 16.77B | ||
BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 131.79 | 14.24B | ||
HIMS | HIMS & HERS HEALTH INC | 78.1 | 12.06B | ||
DVA | DAVITA INC | 14.68 | 10.24B | ||
CHE | CHEMED CORP | 24.32 | 8.39B | ||
CRVL | CORVEL CORP | 31.32 | 5.74B | ||
OPCH | OPTION CARE HEALTH INC | 25.78 | 5.23B | ||
GH | GUARDANT HEALTH INC | N/A | 4.80B |
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company is headquartered in Friendswood, Texas and currently employs 761 full-time employees. The company went IPO on 2019-07-25. The Company’s portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-Melanoma is its risk stratification gene expression profile (GEP) test that predicts the likelihood of positive sentinel lymph node and the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM). DecisionDx-SCC is its GEP test for use in patients with cutaneous squamous cell carcinoma (SCC).
CASTLE BIOSCIENCES INC
505 S Friendswood Drive, Suite 401
Friendswood TEXAS 77546 US
CEO: Derek J. Maetzold
Employees: 761
Phone: 18667889007
The current stock price of CSTL is 16.2 USD. The price decreased by -0.18% in the last trading session.
The exchange symbol of CASTLE BIOSCIENCES INC is CSTL and it is listed on the Nasdaq exchange.
CSTL stock is listed on the Nasdaq exchange.
15 analysts have analysed CSTL and the average price target is 39.1 USD. This implies a price increase of 141.36% is expected in the next year compared to the current price of 16.2. Check the CASTLE BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CASTLE BIOSCIENCES INC (CSTL) has a market capitalization of 467.69M USD. This makes CSTL a Small Cap stock.
CASTLE BIOSCIENCES INC (CSTL) currently has 761 employees.
CASTLE BIOSCIENCES INC (CSTL) has a support level at 16.1 and a resistance level at 16.24. Check the full technical report for a detailed analysis of CSTL support and resistance levels.
The Revenue of CASTLE BIOSCIENCES INC (CSTL) is expected to decline by -10.49% in the next year. Check the estimates tab for more information on the CSTL EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CSTL does not pay a dividend.
CASTLE BIOSCIENCES INC (CSTL) will report earnings on 2025-08-04, after the market close.
The PE ratio for CASTLE BIOSCIENCES INC (CSTL) is 31.15. This is based on the reported non-GAAP earnings per share of 0.52 and the current share price of 16.2 USD. Check the full fundamental report for a full analysis of the valuation metrics for CSTL.
The outstanding short interest for CASTLE BIOSCIENCES INC (CSTL) is 5.39% of its float. Check the ownership tab for more information on the CSTL short interest.
ChartMill assigns a fundamental rating of 5 / 10 to CSTL. No worries on liquidiy or solvency for CSTL as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months CSTL reported a non-GAAP Earnings per Share(EPS) of 0.52. The EPS increased by 145.22% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -1.01% | ||
ROE | -1.15% | ||
Debt/Equity | 0.02 |
ChartMill assigns a Buy % Consensus number of 88% to CSTL. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of -341.51% and a revenue growth -10.49% for CSTL